Cessatech (8GN) Stock Overview

Cessatech A/S engages in identifying and developing drugs for the treatment of medical unmet need in children in Denmark. The company's lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for magnetic resonance imaging scanning; and CT003, a local anesthetic gel for open wounds. The company has a collaboration and license agreement with Ventis Pharma Corporation to develop and formulate pain management therapies. Cessatech A/S was incorporated in 2020 and is based in Copenhagen, Denmark.